Research peptides for weight regulation and metabolic studies. Incretin agonists (Semaglutide, Tirzepatide, Retatrutide) and cellular enzyme inhibitors (5-Amino-1MQ).
15 products in this category
The "Weight Loss" series isn't curated around market noise but around the actual scientific arc of incretin therapy. Between 2017 and 2026, endocrinology moved through three distinct molecular classes - selective GLP-1, dual GLP-1+GIP twincretin, triple GLP-1+GIP+glucagon agonist - and each successive class raised the ceiling for pharmacological body mass reduction.
Semaglutide is the molecule that defined the modern era. STEP-1 showed 14.9% mean body mass reduction at 68 weeks on 2.4 mg weekly - a new benchmark against which every subsequent compound is measured. Tirzepatide is the next turn - combining GLP-1 with GIP at balanced twincretin affinity. SURMOUNT-1 (NEJM 2022) delivered 22.5% at 72 weeks. That was the first time a twincretin class outperformed monotherapy.
Retatrutide takes the next step - triple agonism of GLP-1 + GIP + glucagon receptors. The glucagon component stimulates energy expenditure in brown fat without significantly raising blood sugar, because GLP-1 compensates. TRIUMPH-1 (NEJM 2023) delivered 24.2% at 48 weeks. Beyond the GLP-1 arc sits an unusual flank route - 5-Amino-1MQ, a selective NNMT inhibitor (Sauve, Cornell, Nature 2014) that raises caloric expenditure rather than reducing intake. Which one to research first depends on the specific incretin question, not on the loudest headline.
Related resources: · ·
Filters
Price range
€40-€129
Purity
Vial size
Form
No active filters
15 results
for fat metabolism
Out of stockfat-targeting
Out of stockamylin / CagriSema
Out of stockGLP-1 first-gen
Out of stockGLP-1/GCG dual
Out of stockoral GLP-1
Out of stockGLP-1/GCG dual
Out of stockfor metabolism
